Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | STAT6 | P42226 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974625 | 0.93 | TOP1 (0.77) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL10130708 | 0.92 | TOP1 (0.76) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2031817 | 0.92 | TOP1 (0.76) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL7976717 | 0.91 | TOP1 (0.75) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL7976814 | 0.91 | TOP1 (0.75) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL7626555 | 0.90 | TOP1 (0.73) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL10983845 | 0.90 | TOP1 (0.73) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL28220285 | 0.90 | TOP1 (0.73) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL9559911 | 0.90 | MEN1 (0.71) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL11197250 | 0.89 | TOP1 (0.72) | TOP1ALDH1A1GLAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-1883407-A4 | COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS | COMBINATORX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1883407-A1 | COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS | CombinatoRx, Incorporated (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20060264384-A1 | Compositions and methods for treatment for neoplasms | COMBINATORX, INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006122007-A1 | COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2006-11-16 | — | — | WO | disclosed |
| US-RE32518-E | Camptothecin derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1987-10-13 | — | — | US | disclosed |
| US-4399282-A | 7-HYDROXYALKYL DERIVATIVES USING FREE RADICAL CATALYSTS; ANTITUMOR AND -CARCINOGENIC AGENTS; NONTOXIC | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1983-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885ALDH1A1 3441/4885GLA 1569/4885 |
| US-20060264384-A1 | Compositions and methods for treatment for neoplasms | MGMT, TP53, HCCS | TOP1 201/4885ALDH1A1 1813/4885GLA 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.